|1.||Sadakane, Chiharu: 1 article (10/2009)|
|2.||Inagaki, Yayoi: 1 article (10/2009)|
|3.||Koseki, Junichi: 1 article (10/2009)|
|4.||Shindo, Shoichiro: 1 article (10/2009)|
|5.||Takeda, Shuichi: 1 article (10/2009)|
|6.||Hasegawa, Yoshihiro: 1 article (10/2009)|
|7.||Takeda, Hiroshi: 1 article (10/2009)|
|8.||Hattori, Tomohisa: 1 article (10/2009)|
|1.||IGA Glomerulonephritis (IGA Nephropathy)
10/01/2009 - "The administration of TJN-259 to mice with spontaneous IgA nephropathy decreased the incidence of mesangial expansion as well as the number of nuclei per glomerular cross-section in comparison with that of non-treated mice. "
10/01/2009 - "With regard to spontaneous IgA nephropathy, we investigated the effects of TJN-259 administered from 28 to 40 weeks. "
10/01/2009 - "TJN-259 improves mesangial lesions in experimental immunoglobulin A nephropathy in ddY mice."
10/01/2009 - "In addition, TJN-259 treatment prevented the increase in the incidence of mesangial expansion, crescent formation, and segmental sclerosis in glomeruli in accelerated IgA nephropathy. "
10/01/2009 - "This study was performed in order to elucidate the antinephritic effects of TJN-259 in experimental immunoglobulin A (IgA) nephropathy. "
|1.||Immunoglobulin A (IgA)
|2.||Transforming Growth Factor beta1 (TGF beta 1)
|3.||Collagen Type IV (Type IV Collagen)
|4.||Transforming Growth Factors (Transforming Growth Factor)
|5.||Dihydrotachysterol (AT 10)